within Pharmacolibrary.Drugs.D_Dermatologicals.D10A_AntiAcnePreparationsForTopicalUse.D10AX05_Dapsone;

model Dapsone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 3.611111111111112e-07,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0011200000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0015,
    Tlag = 720,
    Vdp = 0.0008,
    k12 = 7e-06,
    k21 = 7e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dapsone</td></tr><tr><td>ATC code:</td><td>D10AX05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.12</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.3</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dapsone is an antibacterial sulfone drug primarily used for the treatment of leprosy (Hansen's disease), dermatitis herpetiformis, and as a prophylactic treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients. Dapsone is still approved and in use today, especially in combination therapy for leprosy and for certain skin conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single oral 100 mg dose.</p><h4>References</h4><ol><li><p>Mirochnick, M, et al., &amp; Spector, SA (2001). Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. <i>Clinical pharmacology and therapeutics</i> 70(1) 24–32. DOI:<a href=\"https://doi.org/10.1067/mcp.2001.115891\">10.1067/mcp.2001.115891</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11452241/\">https://pubmed.ncbi.nlm.nih.gov/11452241</a></p></li><li><p>Mirochnick, M, et al., &amp; McNamara, J (1999). Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. <i>Antimicrobial agents and chemotherapy</i> 43(11) 2586–2591. DOI:<a href=\"https://doi.org/10.1128/AAC.43.11.2586\">10.1128/AAC.43.11.2586</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10543733/\">https://pubmed.ncbi.nlm.nih.gov/10543733</a></p></li><li><p>Gatti, G, et al., &amp; Bassetti, D (1995). Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. <i>Antimicrobial agents and chemotherapy</i> 39(5) 1101–1106. DOI:<a href=\"https://doi.org/10.1128/AAC.39.5.1101\">10.1128/AAC.39.5.1101</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7625796/\">https://pubmed.ncbi.nlm.nih.gov/7625796</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D10AX05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dapsone;
